BRAF V600E Mutation Analysis in UAE | 1,200 AED | DHA Licensed

Executive Summary & Core Metrics

This BRAF V600E mutation analysis employs Sanger sequencing to deliver 99.9% diagnostic sensitivity for detecting the most common BRAF mutation in tumor tissue. The test is performed exclusively on archival FFPE tissue specimens retrieved via secure medical courier from accredited hospital facilities. Post-analysis telephonic consultation is provided to support result interpretation with our specialist physicians. Key metrics include a turnaround time of 7–8 working days, a fixed price of 1,200 AED, and ISO 9001:2015 certified quality management (Cert: INT/EGQ/2509DA/3139).

Test Overview & Methodology

The BRAF V600E mutation analysis is a targeted molecular assay that identifies the most prevalent BRAF mutation in tumor tissue, guiding precision oncology therapy. Sanger sequencing is utilized as the gold-standard single-gene method, offering high accuracy and rapid actionable results.

Feature	DNA Labs UAE – BRAF V600E Test	Closest Alternative – NGS Panel
Methodology	Sanger Sequencing – gold standard for single-gene mutation	Next‑Generation Sequencing (NGS) – multi‑gene panel
Turnaround Time	7–8 working days	14–21 working days (typical)
Price (AED)	1,200	2,500–3,500+
Sensitivity (V600E)	99.9% diagnostic sensitivity	Variable; often >99% but depends on coverage
Clinical Report	Focused, actionable mutation status	Complex bioinformatics; may include incidental findings

Physician Insight & Safety Protocols

Mr. Prabhakar Reddy Kalathoor (DHA Registration ID: 61713011), Specialist Diagnostic Radiology:

“The BRAF V600E mutation analysis is a technically precise single-gene assay that provides definitive mutation status when correlated with histopathology and imaging findings. As a diagnostic radiologist, I emphasize that while the molecular result is highly accurate, treatment decisions require a multidisciplinary evaluation integrating tumor origin, stage, and prior therapies. No single biomarker should drive clinical action in isolation.”

⚠️ Medication Advisory

Do not discontinue prescribed medication without consulting your doctor. Targeted therapy decisions require a multidisciplinary evaluation; stopping current treatment prematurely may have serious consequences. Always discuss biomarker results with your managing physician before making any changes.

Exclusion Criteria & ER Red Flags

Exclusion Criteria: Insufficient tumor tissue (<50 ng amplifiable DNA), non‑FFPE samples, specimens with >50% necrosis, or microbial contamination. This test is not validated for liquid biopsy cfDNA.
ER Red Flags – Contact emergency services immediately if you experience:
Severe pain, rapid swelling, or heavy bleeding at the biopsy site
Fever >38°C with chills, signs of systemic infection
Shortness of breath or fainting after sample collection

Patient FAQ & Clinical Guidance

1. What is BRAF V600E mutation testing?

BRAF V600E analysis pinpoints a key cancer-causing genetic change, enabling tailored treatment with precision drugs that target the mutated protein. The test identifies the specific V600E substitution in the BRAF gene, which is the most common BRAF alteration across multiple tumor types.

2. Why do I need this test before starting cancer treatment?

Identifying the V600E mutation confirms eligibility for BRAF‑inhibitor therapy, which can shrink tumors and prolong survival in appropriate cancer types. This molecular result is a critical component of precision oncology decision-making.

3. How is the tumor tissue sample obtained for this test?

A biopsy performed at an accredited hospital yields tumor tissue, which is processed into FFPE blocks or slides. These archival specimens are securely transported via medical courier to our laboratory for DNA extraction and Sanger sequencing analysis.

UAE Regulatory & Data Privacy Adherence

Our laboratory operates in full compliance with UAE federal data protection and healthcare technology regulations:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – governing all patient data collection, processing, and storage.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – regulating digital health data and telemedicine frameworks.
Federal Decree-Law No. 4 of 2016 on Medical Liability – ensuring clinical testing safety and informed patient consent protocols.
ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139) for quality management systems.

Clinical & Logistical Metadata

Test Name	BRAF V600E Mutation Analysis
Price (AED)	1,200
Turnaround Time	7–8 working days
Sample Type / Matrix	FFPE Tissue Blocks / Biopsy Slides (Archival Specimen) – Secure Medical Courier Solid Tissue Specimen Retrieval
Methodology Used	Sanger Sequencing
ICD-10-CM Code	Z13.81
LOINC Code	92958-4
DHA Facility License & Laboratory Address	License No. 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| DNA Labs UAE